Bristol-Myers Squibb Co (NYSE:BMY) Shares Bought by Parkside Financial Bank & Trust

Parkside Financial Bank & Trust raised its position in Bristol-Myers Squibb Co (NYSE:BMY) by 9.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,527 shares of the biopharmaceutical company’s stock after acquiring an additional 1,495 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Bristol-Myers Squibb were worth $889,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Lodestar Investment Counsel LLC IL boosted its stake in shares of Bristol-Myers Squibb by 5.2% in the 2nd quarter. Lodestar Investment Counsel LLC IL now owns 113,720 shares of the biopharmaceutical company’s stock valued at $5,157,000 after buying an additional 5,579 shares during the period. Cypress Capital Management LLC boosted its stake in shares of Bristol-Myers Squibb by 21.2% in the 2nd quarter. Cypress Capital Management LLC now owns 154,335 shares of the biopharmaceutical company’s stock valued at $6,999,000 after buying an additional 26,990 shares during the period. Nachman Norwood & Parrott Inc boosted its stake in shares of Bristol-Myers Squibb by 3.5% in the 2nd quarter. Nachman Norwood & Parrott Inc now owns 50,388 shares of the biopharmaceutical company’s stock valued at $2,285,000 after buying an additional 1,687 shares during the period. Edge Wealth Management LLC boosted its stake in shares of Bristol-Myers Squibb by 217.7% in the 2nd quarter. Edge Wealth Management LLC now owns 10,007 shares of the biopharmaceutical company’s stock valued at $452,000 after buying an additional 6,857 shares during the period. Finally, KG&L Capital Management LLC lifted its stake in Bristol-Myers Squibb by 38.6% during the second quarter. KG&L Capital Management LLC now owns 17,104 shares of the biopharmaceutical company’s stock worth $775,000 after purchasing an additional 4,761 shares during the last quarter. 80.40% of the stock is owned by institutional investors.

NYSE BMY traded up $0.44 on Friday, reaching $58.02. The stock had a trading volume of 11,418,626 shares, compared to its average volume of 12,766,524. The company has a debt-to-equity ratio of 1.37, a quick ratio of 3.72 and a current ratio of 3.83. Bristol-Myers Squibb Co has a 12-month low of $42.48 and a 12-month high of $58.46. The business’s 50-day moving average price is $52.90 and its 200 day moving average price is $48.19. The stock has a market cap of $91.88 billion, a P/E ratio of 14.58, a price-to-earnings-growth ratio of 1.31 and a beta of 0.71.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The company had revenue of $6.01 billion during the quarter, compared to analysts’ expectations of $5.89 billion. During the same quarter in the previous year, the business earned $1.09 earnings per share. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. On average, sell-side analysts predict that Bristol-Myers Squibb Co will post 4.33 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Friday, October 4th were paid a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 2.83%. The ex-dividend date of this dividend was Thursday, October 3rd. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.

Several equities research analysts recently weighed in on the company. Bank of America assumed coverage on Bristol-Myers Squibb in a research note on Wednesday, October 16th. They set a “buy” rating and a $60.00 target price for the company. UBS Group boosted their target price on Bristol-Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 23rd. Wolfe Research set a $66.00 target price on Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Friday, November 1st. Atlantic Securities upgraded Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price for the company in a research note on Wednesday, August 14th. Finally, JPMorgan Chase & Co. set a $62.00 target price on Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Friday, September 13th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $56.64.

In related news, SVP John E. Elicker sold 15,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total transaction of $849,900.00. Following the transaction, the senior vice president now owns 74,471 shares of the company’s stock, valued at $4,219,526.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Louis S. Schmukler sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total value of $1,414,000.00. Following the transaction, the insider now directly owns 31,963 shares in the company, valued at approximately $1,807,827.28. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by insiders.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: Catch-Up Contributions

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.